デフォルト表紙
市場調査レポート
商品コード
1470903

がん治療薬市場:適応症別、薬剤クラス別、投与経路別、流通別、最終用途別-2024~2030年の世界予測

Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
がん治療薬市場:適応症別、薬剤クラス別、投与経路別、流通別、最終用途別-2024~2030年の世界予測
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん治療薬市場規模は、2023年に1,757億8,000万米ドルと推定され、2024年には1,884億1,000万米ドルに達し、CAGR 7.64%で2030年には2,944億2,000万米ドルに達すると予測されます。

がん治療薬は、がんの治療、診断、予防に使用される特殊な医薬品です。これらの薬剤は様々な作用機序でがん細胞を標的とするため、悪性腫瘍の管理において極めて重要です。がん治療薬は、化学療法、標的療法、免疫療法、ホルモン療法などいくつかの種類に分類され、それぞれががん治療において独自の役割を果たしています。世界のがん罹患率の急増は、抗がん剤開発への投資や政府資金の増加と相まって、市場の成長を後押ししています。しかし、新薬の開発、試験、承認取得にかかるコストは、メーカーにとって大きな課題となっています。さらに、ゲノム解読技術やバイオテクノロジーの進歩は、個別化医薬品のニーズの高まりとともに、市場成長の有利な機会を生み出しています。

主な市場の統計
基準年[2023] 1,757億8,000万米ドル
予測年[2024] 1,884億1,000万米ドル
予測年 [2030] 2,944億2,000万米ドル
CAGR(%) 7.64%

薬剤クラス別精度の高さと副作用の少なさから、標的治療の重要性が高まる

化学療法には、がん細胞を死滅させたり増殖を抑えたりするための細胞毒性薬の利用が含まれます。化学療法は、最も古くから行われているがん治療のひとつであり、さまざまながん種に使用されます。化学療法は、進行がんや転移したがんに好んで用いられることが多いです。化学療法は単独で、または他の治療法と組み合わせて使用することができます。ホルモン療法は、体内でホルモンを産生する機能を停止させ、ホルモンの作用を阻害することで、ホルモン感受性腫瘍の成長を遅らせたり、阻止したりします。この療法は主に、ホルモンに反応して増殖することが多い乳がんや前立腺がんに用いられます。免疫療法は、体内の自然な防御機能を高めてがんと闘うものです。免疫療法は、体内または実験室で作られた物質を利用して、免疫系の機能を強化・回復させる。免疫療法は、メラノーマ、肺がん、腎臓がんなど、この治療に反応する可能性を示すマーカーを持つがんに好んで用いられます。標的療法は、がんの増殖と生存に寄与する特定の遺伝子、タンパク質、または組織環境を標的とします。この種の治療法は、健康な細胞へのダメージを抑えながら、がん細胞の増殖と蔓延を阻止します。標的療法は、ある種の肺がん、乳がん、大腸がんなど、これらの薬剤の標的となりうる遺伝子変異を有するがんに特に用いられます。

最終用途がん専門クリニックの拡大ががん治療薬の需要を加速

在宅ヘルスケアはがん治療薬の需要が大幅に増加しています。患者や家族は在宅医療をより快適なものと感じ、頻繁な通院に伴う心理的ストレスを軽減することが多いです。病院はがん治療薬投与の重要な終着点であり、特に高度なインフラと綿密な医学的監視を必要とする治療に適しています。病院は幅広い種類のがんに対応しており、入院治療が必要な重篤な症例を扱うことも多いです。がん専門クリニックは、在宅医療と病院の中間に位置し、外来で専門的なケアを提供します。こうしたクリニックは、がん患者の継続的な治療とモニタリングにとって極めて重要であり、しばしば最新の薬剤や臨床試験へのアクセスを容易にしています。

地域別の洞察

アメリカ地域はがん治療薬の主要市場であり、高いヘルスケア支出、強固な研究開発インフラ、大手製薬会社の強力なプレゼンスがその原動力となっています。新規ドラッグデリバリーシステムや標的治療薬に関する特許がこの国の革新性を際立たせる一方、がん研究・イニシアチブへの多額の投資はがん撲滅へのコミットメントを強調するものです。欧州市場は、がん治療薬の開発と承認に適した環境を促進する規制状況の調和が特徴です。加盟国間の価格感応度によって差別化されたこの市場では、革新的な治療法とともに費用対効果の高いがん治療ソリューションが求められています。中東・アフリカ地域は多様な市場環境を示しており、湾岸協力会議(GCC)諸国は革新的ながん治療に対する高い購買力を示す一方、サハラ以南のアフリカ諸国はアクセシビリティと手頃な価格を重視しています。APAC地域のがん治療薬市場は、中間層の増加、ヘルスケア支出の増加、ヘルスケア改革を目指す政府のイニシアチブに後押しされ、急速に拡大しています。がん研究開発において重要な役割を担っているAPAC諸国は、国内および世界のがん市場で躍進しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、がん治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、がん治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.がん治療薬市場の市場規模および予測は?

2.がん治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.がん治療薬市場の技術動向と規制枠組みは?

4.がん治療薬市場における主要ベンダーの市場シェアは?

5.がん治療薬市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中でがんの罹患率が急増
      • がん治療薬開発への投資と政府資金の増加
      • パーソナライズ医療の研究開発の拡大
    • 抑制要因
      • 精密医療治療に伴う高コスト
    • 機会
      • ゲノム配列解析技術とバイオテクノロジーの進歩
      • バイオマーカー主導の医薬品開発の発展
    • 課題
      • 厳しい規制要件と医薬品開発の複雑さ
  • 市場セグメンテーション分析
    • 薬物クラス:精度と副作用の少なさから標的療法の重要性が高まっている
    • 最終用途:がん専門クリニックの継続的な拡大により、がん治療薬の需要が加速
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 がん治療薬市場適応症別

  • 膀胱がん
  • 乳がん
  • 子宮頸がん
  • 大腸がん
  • 食道がん
  • 腎臓がん
  • 肝臓がん
  • 肺がん
  • 前立腺がん
  • 胃がん

第7章 がん治療薬市場薬剤クラス別

  • 化学療法
  • ホルモン療法
  • 免疫療法
  • 標的療法

第8章 がん治療薬市場:投与経路別

  • 静脈内
  • オーラル
  • 話題

第9章 がん治療薬市場配布元

  • オフライン薬局
  • オンライン薬局

第10章 がん治療薬市場:最終用途別

  • 在宅ヘルスケア
  • 病院
  • がん専門クリニック

第11章 南北アメリカのがん治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域のがん治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカのがん治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス、2023
  • 競合シナリオ分析
    • FDA、高リスク前立腺がん治療薬としてXTANDIを承認
    • 武田薬品のFRUZAQLAが転移性大腸がんの治療薬としてFDAの承認を取得
    • FDA、転移性大腸がんの新たな治療薬、武田薬品のFRUZAQLAを承認
  • 戦略分析と提言

第15章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ONCOLOGY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 299. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 300. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 325. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 326. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 337. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 338. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 349. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 350. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 355. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 356. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 357. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 358. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 359. FRANCE ONCOLOGY DRUGS
目次
Product Code: MRR-434CCDA05255

[194 Pages Report] The Oncology Drugs Market size was estimated at USD 175.78 billion in 2023 and expected to reach USD 188.41 billion in 2024, at a CAGR 7.64% to reach USD 294.42 billion by 2030.

Oncology drugs are specialized pharmaceutical agents used in the treatment, diagnosis, and prevention of cancer. These drugs are pivotal in the management of malignancies as they target cancer cells with various mechanisms of action. Oncology drugs can be categorized into several types, including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others, each playing a unique role in oncology care. The surging prevalence of cancer worldwide, coupled with the increase in investments and government funding in the development of cancer drugs, propel the market growth. However, the cost of developing, testing, and securing regulatory approval for new drugs poses a significant challenge to the manufacturers. Furthermore, advancements in genomic sequencing technologies and biotechnology, along with the growing need for personalized medicines, create lucrative opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 175.78 billion
Estimated Year [2024] USD 188.41 billion
Forecast Year [2030] USD 294.42 billion
CAGR (%) 7.64%

Drug Class: Growing significance of targeted therapy due to its precision and lower side effects

Chemotherapy involves the utilization of cytotoxic drugs to kill or hamper the growth of cancer cells. It is among the oldest forms of cancer treatment and can be used across various cancer types. Chemotherapy is often preferred for advanced cancers or cancers that have metastasized. It can be used as a sole treatment & in combination with other therapies. Hormonal therapy slows or prevents the growth of hormone-sensitive tumors by stopping the body's ability to produce hormones & by interfering with hormone action. This therapy is primarily used for breast and prostate cancers, which often grow in response to hormones. Immunotherapy boosts the body's natural defenses to combat cancer. It utilizes substances made by the body or in a laboratory to enhance and restore immune system function. Immunotherapy is preferred for cancers that have markers indicating they may respond to this treatment, such as melanoma, lung cancer, and kidney cancer. Targeted therapy targets the specific genes, proteins, or the tissue environment contributing to cancer growth and survival. This type of therapy stops the growth and prevalence of cancer cells while limiting damage to healthy cells. Targeted therapy is specifically used for cancers with genetic mutations that can be targeted with these drugs, such as certain types of lung, breast, and colorectal cancers.

End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs

Home healthcare has seen a significant uptick in the demand for oncology drugs, attributed largely to the increasing preference for at-home treatments. Patients and families often find home healthcare options more comfortable, reducing the psychological stress associated with frequent hospital visits. Hospitals remain a critical endpoint for the administration of oncology drugs, especially for treatments that require advanced infrastructure and close medical supervision. They cater to a wide spectrum of cancers, often dealing with more severe cases that necessitate in-patient care. Specialty cancer clinics offer a middle ground between home healthcare and hospitals, providing specialized care in an outpatient setting. These clinics are pivotal for the ongoing treatment and monitoring of cancer patients, often facilitating access to the latest drugs and clinical trials.

Regional Insights

The American region represents a major market for oncology drugs, driven by high healthcare expenditure, robust research and development infrastructure, and a strong presence of leading pharmaceutical companies. Patents in novel drug delivery systems and targeted therapies highlight the country's innovation, while significant investment in cancer research & initiatives underscores a commitment to combating cancer. The European market is marked by a harmonized regulatory landscape that fosters a conducive environment for oncology drug development and approval. Differentiated by price sensitivity across member states, the market demands cost-effective oncology solutions alongside innovative therapies. The Middle East & Africa region presents a diverse market landscape, with Gulf Cooperation Council (GCC) countries showing high purchasing power for innovative oncology treatments, contrasted with Sub-Saharan Africa's focus on accessibility and affordability. The APAC region's oncology drugs market is rapidly expanding, fueled by a growing middle class, increased healthcare spending, and government initiatives aimed at healthcare reform. The APAC countries with significant players in oncology research and development are making strides in both the domestic and global oncology markets.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Oncology Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncology Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Esophagus Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • Stomach Cancer
  • Drug Class
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Targeted Therapy
  • Route of Administration
    • Intravenous
    • Oral
    • Topical
  • Distribution
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • End-use
    • Home Healthcare
    • Hospitals
    • Specialty Cancer Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Oncology Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncology Drugs Market?

3. What are the technology trends and regulatory frameworks in the Oncology Drugs Market?

4. What is the market share of the leading vendors in the Oncology Drugs Market?

5. Which modes and strategic moves are suitable for entering the Oncology Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of cancer across the globe
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Growing research & development in personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the precision medicine therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic sequencing technologies and biotechnology
      • 5.1.3.2. Development of biomarker-driven drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and the complexity of drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
    • 5.2.2. End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Oncology Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Breast Cancer
  • 6.4. Cervical Cancer
  • 6.5. Colorectal Cancer
  • 6.6. Esophagus Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Lung Cancer
  • 6.10. Prostate Cancer
  • 6.11. Stomach Cancer

7. Oncology Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Immunotherapy
  • 7.5. Targeted Therapy

8. Oncology Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Oncology Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
  • 9.3. Online Pharmacies

10. Oncology Drugs Market, by End-use

  • 10.1. Introduction
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Specialty Cancer Clinics

11. Americas Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves XTANDI for High-Risk Prostate Cancer Management
    • 14.3.2. Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance
    • 14.3.3. FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio